 |
|
|
| |
Safety and Effectiveness of Raltegravir-based HAART in HIV-Subjects after Solid Organ Transplantation
|
| |
| |
Reported by Jules Levin
ICAAC Sept 11-15 2009 San Francisco
Ana Moreno 1*, Maria J. Perez-Elias 1, Jose L. Casado 1, Jesus Fortun 1 , Carmen Quereda 1, Rafael Barcena 2, Santos del Campo 2,
Carmen Gutierrez 3, Oscar Pastor 3, Javier Nuno 4, Ana Fernandez 5 and Santiago Moreno 1
Services of Infectious Diseases1, Liver-Gastroenterology2, Biochemistry3, General and Digestive Surgery4 , and Nephrology5. Hospital Ramón y Cajal. Madrid. Spain.
TX : transplant ; IS :immunosuppressive regimen ; HAART : highly active antiretroviral regimen ; VL0 : baseline HIV-viral load ; RAL :: raltegravir; CllCr: creatinin clearance;; (0: baseline; L:: last value) ; FU:: follow-up time; M:: male sex; RAPA:: rapamycin; FK:: tacrolimus; MF:: mycophenolic acid; ST:: steroids; 3TC:: lamivudine; ABC:: abacavir; TRU: emtricitabine+tenofovir combo (TRUVADA); T-20:: enfuvirtide; TDF:: tenofovir; EFV:: efavirenz; RI:: renal insufficiency; LT:: liver transplant; HD:: haemodialysis
Both patients on T-20 simplified HAART therapy after 7 weeks: P2 to ATRIPLA plus RAL, and P4 to TRUVADA plus maraviroc plus RAL
PI: protease inhibitors; ART: antiretroviral therapy; NRTI; nucleoside analogues; NNRTI: non-nucleoside analogues; D4T; stavudine; ABC: abacavir; DDI; didanosine; 3TC: lamivudine; r//LPV: ritonavir-boosted lopinavir; TRU: emtricitabine+tenofovir combo (TRUVADA);
* treatment withdrawal on day +52 after LT due to suspected renal toxicity related to tenofovir (metabolic acidosis and decreased CrCl)
|
| |
|
|
|
|
|
